152 related articles for article (PubMed ID: 30736983)
61. Genomic instability: The sting of metastasis.
Seton-Rogers S
Nat Rev Cancer; 2018 Feb; 18(3):137. PubMed ID: 29467525
[No Abstract] [Full Text] [Related]
62. Author Correction: Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability.
Galanos P; Pappas G; Polyzos A; Kotsinas A; Svolaki I; Giakoumakis NN; Glytsou C; Pateras IS; Swain U; Souliotis VL; Georgakilas AG; Geacintov N; Scorrano L; Lukas C; Lukas J; Livneh Z; Lygerou Z; Chowdhury D; Sørensen CS; Bartek J; Gorgoulis VG
Genome Biol; 2022 Apr; 23(1):107. PubMed ID: 35484586
[No Abstract] [Full Text] [Related]
63. Strain as hallmark to prevent interruption of breast cancer therapy.
Bergler-Klein J
Eur Heart J Cardiovasc Imaging; 2019 Dec; 20(12):1353-1354. PubMed ID: 31596457
[No Abstract] [Full Text] [Related]
64. Mechanisms of Genomic Instability in Breast Cancer.
Duijf PHG; Nanayakkara D; Nones K; Srihari S; Kalimutho M; Khanna KK
Trends Mol Med; 2019 Jul; 25(7):595-611. PubMed ID: 31078431
[TBL] [Abstract][Full Text] [Related]
65. A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients.
Shimizu H; Nakayama KI
EBioMedicine; 2019 Aug; 46():150-159. PubMed ID: 31358476
[TBL] [Abstract][Full Text] [Related]
66. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
Chu W; Zhang X; Qi L; Fu Y; Wang P; Zhao W; Du J; Zhang J; Zhan J; Wang Y; Zhu WG; Yu Y; Zhang H
Cancer Res; 2020 Jul; 80(13):2737-2750. PubMed ID: 32312833
[TBL] [Abstract][Full Text] [Related]
67. Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Testa U; Castelli G; Pelosi E
Med Sci (Basel); 2020 Mar; 8(1):. PubMed ID: 32210163
[TBL] [Abstract][Full Text] [Related]
68. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets.
Liang Y; Zhang H; Song X; Yang Q
Semin Cancer Biol; 2020 Feb; 60():14-27. PubMed ID: 31421262
[TBL] [Abstract][Full Text] [Related]
69. Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B Breast Cancer: A Pilot Study.
Camargo-Herrera V; Castellanos G; Rangel N; Jiménez-Tobón GA; Martínez-Agüero M; Rondón-Lagos M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674062
[TBL] [Abstract][Full Text] [Related]
70. Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence.
Čižmáriková M; Michalková R; Mirossay L; Mojžišová G; Zigová M; Bardelčíková A; Mojžiš J
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002335
[TBL] [Abstract][Full Text] [Related]
71. The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches.
Deacon S; Walker L; Radhi M; Smith S
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444417
[TBL] [Abstract][Full Text] [Related]
72. CNVs in 8q24.3 do not influence gene co-expression in breast cancer subtypes.
Hernández-Gómez C; Hernández-Lemus E; Espinal-Enríquez J
Front Genet; 2023; 14():1141011. PubMed ID: 37274786
[TBL] [Abstract][Full Text] [Related]
73. Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.
Pipek O; Alpár D; Rusz O; Bödör C; Udvarnoki Z; Medgyes-Horváth A; Csabai I; Szállási Z; Madaras L; Kahán Z; Cserni G; Kővári B; Kulka J; Tőkés AM
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239898
[TBL] [Abstract][Full Text] [Related]
74. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma.
Kumar S; Zhao J; Talluri S; Buon L; Mu S; Potluri LB; Liao C; Shi J; Chakraborty C; Gonzalez GB; Tai YT; Patel J; Pal J; Mashimo H; Samur MK; Munshi NC; Shammas MA
Gastroenterology; 2023 Aug; 165(2):357-373. PubMed ID: 37178737
[TBL] [Abstract][Full Text] [Related]
75. Extracellular Vesicles in Breast Cancer: From Biology and Function to Clinical Diagnosis and Therapeutic Management.
Loric S; Denis JA; Desbene C; Sabbah M; Conti M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108371
[TBL] [Abstract][Full Text] [Related]
76. COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis.
Hancock JL; Kalimutho M; Straube J; Lim M; Gresshoff I; Saunus JM; Lee JS; Lakhani SR; Simpson KJ; Bush AI; Anderson RL; Khanna KK
J Exp Clin Cancer Res; 2023 Apr; 42(1):90. PubMed ID: 37072858
[TBL] [Abstract][Full Text] [Related]
77. SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis.
Njouendou AJ; Szarvas T; Tiofack AAZ; Kenfack RN; Tonouo PD; Ananga SN; Bell EHMD; Simo G; Hoheisel JD; Siveke JT; Lueong SS
Mol Cancer; 2023 Mar; 22(1):52. PubMed ID: 36932385
[TBL] [Abstract][Full Text] [Related]
78. Chemotherapeutic Potential of Saikosaponin D: Experimental Evidence.
Manoharan S; Deivendran B; Perumal E
J Xenobiot; 2022 Dec; 12(4):378-405. PubMed ID: 36547471
[TBL] [Abstract][Full Text] [Related]
79. MLSP: A bioinformatics tool for predicting molecular subtypes and prognosis in patients with breast cancer.
Zhu J; Kong W; Huang L; Wang S; Bi S; Wang Y; Shan P; Zhu S
Comput Struct Biotechnol J; 2022; 20():6412-6426. PubMed ID: 36467575
[TBL] [Abstract][Full Text] [Related]
80. EIF4A3-induced circBRWD3 promotes tumorigenesis of breast cancer through miR-142-3p_miR-142-5p/RAC1/PAK1 signaling.
Meng X; Li W; Meng Z; Li Y
BMC Cancer; 2022 Nov; 22(1):1225. PubMed ID: 36443711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
